CIRCIO HOLDING (CRNA.OL) Stock Price, Forecast & Analysis
Europe - Euronext Oslo - OSL:CRNA - NO0013033795 - Common Stock
CRNA.OL Key Statistics, Chart & Performance
The current stock price of CRNA.OL is 1.22 NOK. In the past month the price decreased by -13.11%. In the past year, price increased by 72.8%.
CRNA.OL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1AE.DE | ARGENX SE | 66.5 | 43.32B | ||
| ARGX.BR | ARGENX SE | 66.47 | 43.30B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 20.52B | ||
| ABVX.PA | ABIVAX SA | N/A | 8.53B | ||
| 2X1.DE | ABIVAX SA | N/A | 8.59B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.85B | ||
| GXE.DE | GALAPAGOS NV | N/A | 1.86B | ||
| 5CV.DE | CUREVAC NV | 6.71 | 876.36M | ||
| NANO.PA | NANOBIOTIX | N/A | 877.52M | ||
| 6IV.DE | INVENTIVA SA | N/A | 753.57M | ||
| IVA.PA | INVENTIVA SA | N/A | 810.87M | ||
| PHIL.MI | PHILOGEN SPA | 19.82 | 660.82M |
Related stock screener links
About CRNA.OL
Company Profile
Circio Holding ASA is a biotechnology company, which engages in developing novel circular RNA and immunotherapy medicines. The company is headquartered in Lysaker, Akershus and currently employs 9 full-time employees. The company went IPO on 2014-06-16. The firm is engaged in the biotechnology and develops ribonucleic acid (RNA) and immunotherapy medicines. The firm offers circular RNA (circRNA) platform to develop circRNA medicines for cancer, vaccines, protein replacement for genetic disorders and cell therapy. The circVec technology is based on a modular genetic cassette design for efficient biogenesis of multifunctional circRNA from DNA-based vectors that can be deployed for multiple purposes. Circios strategy is to develop circAde cancer medicines in-house and seek partnerships in other therapeutic areas to demonstrate the broad potential of the circVec platform and accelerate circRNA pipeline development. Circio’s second clinical program is an immunotherapy targeting KRAS driver mutations.
Company Info
CIRCIO HOLDING
Vollsveien 19
Lysaker AKERSHUS NO
Employees: 9
Phone: 4721398810
CIRCIO HOLDING / CRNA.OL FAQ
What does CIRCIO HOLDING do?
Circio Holding ASA is a biotechnology company, which engages in developing novel circular RNA and immunotherapy medicines. The company is headquartered in Lysaker, Akershus and currently employs 9 full-time employees. The company went IPO on 2014-06-16. The firm is engaged in the biotechnology and develops ribonucleic acid (RNA) and immunotherapy medicines. The firm offers circular RNA (circRNA) platform to develop circRNA medicines for cancer, vaccines, protein replacement for genetic disorders and cell therapy. The circVec technology is based on a modular genetic cassette design for efficient biogenesis of multifunctional circRNA from DNA-based vectors that can be deployed for multiple purposes. Circios strategy is to develop circAde cancer medicines in-house and seek partnerships in other therapeutic areas to demonstrate the broad potential of the circVec platform and accelerate circRNA pipeline development. Circio’s second clinical program is an immunotherapy targeting KRAS driver mutations.
Can you provide the latest stock price for CIRCIO HOLDING?
The current stock price of CRNA.OL is 1.22 NOK. The price decreased by -0.97% in the last trading session.
Does CIRCIO HOLDING pay dividends?
CRNA.OL does not pay a dividend.
How is the ChartMill rating for CIRCIO HOLDING?
CRNA.OL has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
On which exchange is CRNA.OL stock listed?
CRNA.OL stock is listed on the Euronext Oslo exchange.
What sector and industry does CIRCIO HOLDING belong to?
CIRCIO HOLDING (CRNA.OL) operates in the Health Care sector and the Biotechnology industry.
Can you provide the PE ratio for CRNA stock?
The PE ratio for CIRCIO HOLDING (CRNA.OL) is 0.44. This is based on the reported non-GAAP earnings per share of 2.79 and the current share price of 1.22 NOK.
CRNA.OL Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to CRNA.OL. When comparing the yearly performance of all stocks, CRNA.OL is one of the better performing stocks in the market, outperforming 84.57% of all stocks.
CRNA.OL Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to CRNA.OL. CRNA.OL has a bad profitability rating. Also its financial health evaluation is rather negative.
CRNA.OL Financial Highlights
Over the last trailing twelve months CRNA.OL reported a non-GAAP Earnings per Share(EPS) of 2.79. The EPS increased by 117.43% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | 451.2% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
CRNA.OL Forecast & Estimates
7 analysts have analysed CRNA.OL and the average price target is 3.06 NOK. This implies a price increase of 150.82% is expected in the next year compared to the current price of 1.22.
For the next year, analysts expect an EPS growth of -109.61% and a revenue growth -100% for CRNA.OL